This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Menu
Close
UC is the most common type of inflammatory bowel disease (IBD).1 IBD is the definition of a group of diseases that cause long-term inflammation in the digestive system, which can lead to considerable damage on the digestive organs and make it harder for them to function.2,3
The exact cause of IBD is unknown, but it is thought to involve a combination of genes, the immune system and environmental factors.3,4
Uncontrolled UC shows up as inflammation in the large intestine (colon) and rectum, and only affects the innermost lining of these organs. This inflammation can lead to painful sores, such as ulcers, which can then bleed and cause blood in stools (the main symptom of UC).4,5
Explore here how uncontrolled UC may manifest in patients. Learn how this may affect patients’ perception of and treatment expectations for UC. Gain insights into the prevalence and impact of uncontrolled UC and familiarise yourself with tools that were designed to aid in bridging the gap between healthcare professionals and patients to strive for alignment on treatment goals.
Identifying the
unspoken realities behind uncontrolled UC
Why might patients with UC settle for “OK”?
The prevalence and impact of uncontrolled UC
Resources to help
look beyond “OK” for patients’ UC
Xeljanz®(tofacitinib citrate) Prescribing information and Inflectra®(infliximab) Prescribing information.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024